Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.sbqKNnJW.js ...

AbCellera announced that it has expanded its existing collaboration with AbbVie Inc. to include the discovery of T-cell engagers (TCE) in oncology.

This year more than ever, from the grand halls of the fairs to the intimate installations scattered throughout the cities, these events of global resonance have been more than just showcases of ...

The Benchmark Company has recently reduced AbCellera Biologics Inc (ABCL) stock to Hold rating, as announced on August 20, 2024, according to Finviz. Earlier, on February 22, 2024, The Benchmark ...

Carl Hansen, Ph.D., founder and CEO of AbCellera, expressed optimism about the expanded collaboration, which aims to deliver novel cancer immunotherapies to patients. Under the terms of the expanded ...

AbCellera is expanding its collaboration with pharmaceutical company AbbVie to include the discovery of T-cell engagers in oncology. The new agreement will see the Canadian developer of antibody ...

“We are pleased to broaden our AbbVie collaboration and look forward to using AbCellera’s TCE platform to bring novel cancer immunotherapies to patients in need,” said Carl Hansen, Ph.D ...